Drug Profile
BI 836880
Alternative Names: Anti-VEGF/Ang2 Nanobody®; BI-836880; Bi-specific Anti-VEGF/Ang2 Nanobody®; VEGF/Ang2 Nanobody ®Latest Information Update: 23 Nov 2023
Price :
$50
*
At a glance
- Originator Ablynx
- Developer Boehringer Ingelheim
- Class Antineoplastics; Bispecific antibodies; Eye disorder therapies; Immunotherapies
- Mechanism of Action Angiopoietin-2 inhibitors; Vascular endothelial growth factor A inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Anal cancer; Solid tumours
- Phase I/II Wet age-related macular degeneration
- Phase I Liver cancer; Squamous cell cancer
- Preclinical Nasopharyngeal cancer
- No development reported Non-small cell lung cancer
Most Recent Events
- 01 Nov 2023 Boehringer Ingelheim completes a phase I/II trial for Wet age related macular degeneration USA (Intravitreal, Injection) (NCT03861234) (EudraCT2017-001221-40)
- 28 Jul 2023 No recent reports of development identified for phase-I development in Non-small-cell-lung-cancer(Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in Australia (IV, Infusion)
- 28 Jul 2023 No recent reports of development identified for phase-I development in Non-small-cell-lung-cancer(Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in France (IV, Infusion)